MS drug gets green light
The Therapeutic Goods Administration has approved injectable pegylated interferon beta-1a for the treatment of relapsing multiple sclerosis.
The medication, marketed as Plegridy, is a new version of interferon therapy designed to maintain its effects for longer in the body, so that injections are needed once every two weeks instead of weekly.
Plegridy received European and US marketing authorisation earlier in 2014. Its approval was based